-
公开(公告)号：US20100316598A1
公开(公告)日：2010-12-16
申请号：US12763354
申请日：2010-04-20
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号：US20100316597A1
公开(公告)日：2010-12-16
申请号：US12763337
申请日：2010-04-20
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号：US07790851B2
公开(公告)日：2010-09-07
申请号：US12435218
申请日：2009-05-04
申请人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
发明人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
IPC分类号： C07K14/52
CPC分类号： C07K14/715 , A61K38/00
摘要： Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”
-
公开(公告)号：US20120294798A1
公开(公告)日：2012-11-22
申请号：US13535832
申请日：2012-06-28
IPC分类号： A61K38/20 , A61P35/02 , A61K51/08 , A61N5/00 , A61K38/21 , A61P37/04 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/02
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
摘要翻译： 描述了使用具有IL-21功能活性的分子治疗具有癌症的哺乳动物的方法。 具有IL-21功能活性的分子包括与人IL-21多肽序列具有同源性的多肽和与具有IL-21功能活性的多肽融合的蛋白质。 分子可以用作单一疗法或与其他已知的癌症治疗剂组合使用。
-
公开(公告)号：US20110086004A1
公开(公告)日：2011-04-14
申请号：US12947957
申请日：2010-11-17
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
-
公开(公告)号：US20100316600A1
公开(公告)日：2010-12-16
申请号：US12771142
申请日：2010-04-30
CPC分类号： C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要： Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
摘要翻译： 描述了使用具有IL-21功能活性的分子治疗具有癌症的哺乳动物的方法。 具有IL-21功能活性的分子包括与人IL-21多肽序列具有同源性的多肽和与具有IL-21功能活性的多肽融合的蛋白质。 分子可以用作单一疗法或与其他已知的癌症治疗剂组合使用。
-
公开(公告)号：US07851594B2
公开(公告)日：2010-12-14
申请号：US11829011
申请日：2007-07-26
申请人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
发明人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
IPC分类号： C07K14/52
CPC分类号： C07K14/715 , A61K38/00
摘要： Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”
-
公开(公告)号：US20100311120A1
公开(公告)日：2010-12-09
申请号：US12832882
申请日：2010-07-08
申请人： SCOTT R. PRESNELL , WENFENG XU , WYNE KINDSVOGEL , ZHI CHEN , STEVEN D. HUGHES
发明人： SCOTT R. PRESNELL , WENFENG XU , WYNE KINDSVOGEL , ZHI CHEN , STEVEN D. HUGHES
CPC分类号： C07K14/715 , A61K38/00
摘要： Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as “Zcytor16.”
摘要翻译： 细胞因子及其受体已被证明在基础研究和治疗方面都是有用的。 本发明提供与称为“Zcytor16”的新的人类细胞因子受体相关的多核苷酸，载体，细胞和生产方法。
-
公开(公告)号：US20090264624A1
公开(公告)日：2009-10-22
申请号：US12435218
申请日：2009-05-04
申请人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
发明人： Scott R. Presnell , Wenfeng Xu , Wayne Kindsvogel , Zhi Chen , Steven D. Hughes
IPC分类号： C07K14/715
CPC分类号： C07K14/715 , A61K38/00
摘要： Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”
摘要翻译： 细胞因子及其受体已被证明在基础研究和治疗方面都是有用的。 本发明提供了称为“Zcytor16”的新的人细胞因子受体。
-
30.发明授权Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies 有权抗IL-20抗体的免疫偶联物和表达抗IL-20抗体的杂交瘤细胞系公开(公告)号：US07393684B2
公开(公告)日：2008-07-01
申请号：US10994116
申请日：2004-11-19
申请人： Wenfeng Xu , Wayne R. Kindsvogel , Zhi Chen , Steven D. Hughes , Yasmin A. Chandrasekher , Stacey R. Dillon , Joyce M. Lehner , Anthony W. Siadak , Pallavur V. Sivakumar , Margaret D. Moore
发明人： Wenfeng Xu , Wayne R. Kindsvogel , Zhi Chen , Steven D. Hughes , Yasmin A. Chandrasekher , Stacey R. Dillon , Joyce M. Lehner , Anthony W. Siadak , Pallavur V. Sivakumar , Margaret D. Moore
IPC分类号： C12N5/20
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
摘要翻译： 本发明涉及阻断IL-20多肽分子的活性。 IL-20是涉及炎症过程和人类疾病的细胞因子。 IL-20RA / IL-20RB是IL-20的常见受体。 本发明包括抗IL-20抗体和结合配偶体，以及使用这种抗体和结合配偶体拮抗IL-20的方法。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.056 秒)
